Skip to content

US · ALDX · BIOTECHNOLOGY

Aldeyra The (ALDX) intrinsic value and stock valuation

$0.84as of 2026-11-21 · Mkt cap 96.51M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aldeyra The DCF and intrinsic value

InvestorsCraft values ALDX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ALDX’s statements →

Aldeyra The Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Lexington, MA 02421 aldeyra.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-33.85M
20112025
Free cash flow
-$-33.35M
20112025
Total equity
$44.3M-5.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-35.27M-$-60.12M-$-42.79M-$-62.68M-$-56.22M
Net income-$-33.85M-$-55.85M-$-37.54M-$-62.02M-$-57.78M
EPSd-$-563.6K-$-938.97K-$-636.92K-$-1.06M-$-1.07M
Operating cash flow-$-33.35M-$-43.21M-$-30.33M-$-56.64M-$-42.56M
Capital expenditure$0.00$0.00$0.00-$-20K-$-10K
Free cash flow-$-33.35M-$-43.21M-$-30.33M-$-56.65M-$-42.56M
Total assets$72.1M$104.6M$148.3M$181.3M$233.1M
Total debt$15.5M$15.3M$15.7M$16.1M$15.9M
Net debt-$-54.51M-$-39.22M-$-127.17M-$-128.34M-$-213.93M
Total equity$44.3M$71M$119.8M$151M$205.7M
Cash and short-term investments$70M$101.2M$142.8M$174.3M$229.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$25.7M$48.2M$29.5M$47.3M$44.9M
Selling, general and administrative expenses$9.6M$11.9M$13.3M$15.4M$11.3M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$35.3M$60.1M$42.8M$62.7M$56.2M
Cost and expenses$35.3M$60.1M$42.8M$62.7M$56.2M
Interest income$3.32M$6.19M$7.32M$2.35M$190K
Interest expense$1.91M$1.93M$2.07M$1.69M$1.74M
Depreciation and amortization$250K$250K$260K$260K$260K
Ebitda-$-31.69M-$-53.68M-$-35.21M-$-60.07M-$-55.77M
Operating income-$-35.27M-$-60.12M-$-42.79M-$-62.68M-$-56.22M
Total other income/expenses, net$1.42M$4.27M$5.25M$660K-$-1.56M
Income before tax-$-33.85M-$-55.85M-$-37.54M-$-62.02M-$-57.78M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-33.85M-$-55.85M-$-37.54M-$-62.02M-$-57.78M
Weighted average shares outstanding$60.1M$59.5M$58.9M$58.4M$54M
Weighted average diluted shares outstanding$60.1M$59.5M$58.9M$58.4M$54M
Balance sheet
20252024202320222021
Cash and short-term investments$70M$101.2M$142.8M$174.3M$229.8M
Net receivables$0.00$0.00$0.00$3.24M$30K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$71.8M$104.1M$147.8M$181M$232.8M
Property, plant and equipment, net$280K$270K$520K$270K$380K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$280K$530K$520K$270K$380K
Total assets$72.1M$104.6M$148.3M$181.3M$233.1M
Accounts payable$160K$180K$1.34M$130K$1.02M
Short-term debt$15.5M$300K$15.4M$1.16M$460K
Deferred revenue$6M$6M$0.00$0.00$0.00
Total current liabilities$27.8M$18.6M$22.3M$15.4M$11.8M
Long-term debt$0.00$15M$270K$14.9M$15.6M
Deferred revenue, non-current$0.00$0.00$6M$0.00$0.00
Total non-current liabilities$0.00$15M$6.27M$14.9M$15.6M
Capital lease obligations$280K$270K$510K$250K$350K
Total liabilities$27.8M$33.6M$28.5M$30.3M$27.4M
Common stock$60K$60K$60K$60K$60K
Retained earnings-$-483.96M-$-450.11M-$-394.26M-$-356.72M-$-294.69M
Accumulated other comprehensive income (loss)$0.00$40K$0.00-$-100K$0.00
Total equity$44.3M$71M$119.8M$151M$205.7M
Total investments$0.00$46.6M$0.00$29.9M$0.00
Total debt$15.5M$15.3M$15.7M$16.1M$15.9M
Net debt-$-54.51M-$-39.22M-$-127.17M-$-128.34M-$-213.93M
Cash flow statement
20252024202320222021
Net income-$-33.85M-$-55.85M-$-37.54M-$-62.02M-$-57.78M
Depreciation and amortization$250K$250K$260K$260K$260K
Stock-based compensation$6.09M$7.97M$5.75M$8.29M$7.11M
Change in working capital-$-5.18M$5.91M$860K-$-3.44M$7.44M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-20K-$-1.16M$1.2M-$-890K$640K
Net cash provided by operating activities-$-33.35M-$-43.21M-$-30.33M-$-56.64M-$-42.56M
Investments in property, plant and equipment$0.00$0.00$0.00-$-20K-$-10K
Acquisitions, net$0.00$0.00$0.00$20K$0.00
Net cash used for investing activities$47.7M-$-44.92M$30M-$-29.95M-$-10K
Common stock issued$1.12M$120K$310K$1.22M$189.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.12M-$-170K-$-1.27M$1.22M$194.5M
Net change in cash$15.5M-$-88.3M-$-1.6M-$-85.37M$151.9M
Cash at end of period$70M$54.5M$142.8M$144.4M$229.8M
Operating cash flow-$-33.35M-$-43.21M-$-30.33M-$-56.64M-$-42.56M
Capital expenditure$0.00$0.00$0.00-$-20K-$-10K
Free cash flow-$-33.35M-$-43.21M-$-30.33M-$-56.65M-$-42.56M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aldeyra The

        Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

        CEO
        Todd C. Brady
        Employees
        8
        Beta
        1.15

        Explore

        Frequently asked questions

        What is the intrinsic value of Aldeyra The (ALDX)?

        InvestorsCraft does not currently publish an intrinsic value for ALDX. How the IC value is calculated.

        Is ALDX undervalued?

        InvestorsCraft does not publish an undervaluation signal for ALDX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.